Photo by National Institute of Allergy and Infectious Diseases on Unsplash
The gut and immune system connection is real, but the claim that “70% of immunity lives in your gut” is not a validated medical measurement. The phrase is commonly used to emphasize that the intestine is an active immune site. It does not mean that 70% of the immune system can be physically located, measured, or improved through a gut-health program.
Immune function involves tissues and cells throughout the body, including bone marrow, blood, lymph nodes, the spleen, skin, lungs, and the digestive tract. The intestine has a distinctive job because it continually encounters food, microorganisms, and other material from outside the body. It must absorb nutrients while helping protect against infection and limiting unnecessary immune responses to food and to many organisms that normally live in the gut.
Gut microorganisms are part of this system. They participate in normal physiology, including nutrition, development, and immunity. But microbiome science does not support a single ideal gut profile, a universal supplement plan, or broad promises to “boost” immunity. The useful question is not whether the gut matters. It is what a particular study found, in whom, and whether it measured an outcome that matters to patients.
Why the “70%” claim does not hold up
The supplied research does not offer a standardized method for calculating what proportion of a person’s immune system is “in” the gut. The 70% figure is not a diagnostic threshold, a measure of infection risk, or a clinical test of immune health. It cannot tell someone whether their immune system is working well, and it does not establish that changing gut bacteria will improve a fixed portion of immunity.
The underlying idea is more accurate when stated plainly: the intestinal lining is an important barrier and immune environment. It has to manage frequent contact with substances from the outside world without treating every meal or harmless resident organism as a threat. Intestinal tissues, mucus, immune cells, and microbial communities all contribute to that work.
That role should not be confused with making the immune system stronger in all circumstances. Immune activity can be helpful, excessive, poorly directed, or persistent. For that reason, a claim that a food, supplement, or test “boosts immunity” is not meaningful unless it identifies a specific outcome, such as fewer infections in a defined group or a better response to a particular medical treatment.
Digestive symptoms do not automatically indicate an immune disorder. Likewise, a stool sample cannot calculate overall immune health. The intestine is one major site of immune activity within a body-wide system, not the sole control center for immune function.
What gut microbes contribute to normal physiology
Gut microbiota refers to the microorganisms living in the intestine. Microbiome often refers to the collective genes and functions associated with those organisms, although the terms are frequently used interchangeably.
A 2021 review describes intestinal microbes as a functional part of the human organism and discusses their involvement in processes including nutrition, development, and immunity. It also reviews links between altered microbial communities and a range of chronic conditions. Álvarez and colleagues
Microbial communities differ substantially among people and may change with diet, medications, age, illness, and other exposures. This variation makes it difficult to label individual bacteria as universally “good” or “bad.” A bacterial pattern that appears relevant in one study population may not have the same meaning in another person with different health conditions, medicines, diet, or broader microbial community.
Researchers use dysbiosis to describe altered microbial composition, diversity, or function observed in connection with illness or other changes in health. The 2021 review discusses associations between dysbiosis and conditions such as atopy, metabolic syndrome, inflammatory diseases, cancer, and some behavioral disorders. Álvarez and colleagues
Those associations are useful for research, but they do not settle cause and effect. A microbial change may contribute to disease, result from disease, or reflect another factor, such as medication use, diet, bowel habits, or changes in health status. In this article’s interpretation of the review, the breadth of reported associations shows why microbiome findings need careful, condition-specific testing rather than broad conclusions about cause or treatment.
The same caution applies to microbial diversity. Reduced species richness is discussed as a feature associated with dysbiosis in industrialized societies. Álvarez and colleagues That observation does not establish that increasing diversity will prevent disease or improve immune function for every person. Diversity is a research measure, not a stand-alone treatment target for consumers.
What microbiome studies can—and cannot—answer
Microbiome research can compare stool samples from people with and without a health condition, explore microbial patterns linked to diet or medication use, and examine whether those patterns are associated with treatment outcomes. Laboratory and animal studies can also investigate biological pathways that may help explain an observed association.
These methods can identify findings worth further study. On their own, however, they do not prove that a microbial pattern caused a symptom or disease. A change in the relative amount of a bacterium may be scientifically interesting without showing that patients had fewer symptoms, better disease control, fewer infections, or longer survival.
This distinction is especially important for consumer stool testing. The cited studies do not establish that direct-to-consumer microbiome tests can diagnose a general immune problem, explain fatigue or bloating, identify the cause of a skin condition, or select a proven treatment. The clinical usefulness of these tests for such broad purposes remains uncertain.
It also matters when considering “gut reset” plans, restrictive diets, supplements, and microbiome-based products. A product may alter a laboratory result without demonstrating a patient-important benefit. Any intervention claim requires evidence for the specific intervention, dose or formulation where relevant, population, and outcome.
New, severe, persistent, or worsening digestive symptoms should be evaluated on their own merits. Attributing symptoms to an “imbalanced microbiome” may delay assessment for conditions with established diagnostic approaches and treatments.
Fiber and probiotics in melanoma immunotherapy
The most specific intervention-related evidence in the supplied material comes from a 2021 study of people with melanoma receiving immune checkpoint blockade, a type of cancer immunotherapy. Researchers assessed fecal microbiota profiles, reported dietary habits, and commercial probiotic supplement use, alongside preclinical experiments. Spencer and colleagues
Among 128 participants receiving checkpoint blockade, higher reported dietary fiber intake was associated with improved progression-free survival. The association was most pronounced among participants with sufficient reported fiber intake who did not report using commercial probiotic supplements. Spencer and colleagues
This was an association in a defined cancer-treatment population, not established proof that fiber caused better outcomes. People with different dietary patterns may also differ in ways that affect treatment response. The study does not establish that increasing fiber prevents infections, improves general immune function, or produces the same result in people who are not receiving melanoma immunotherapy.
In mouse models, low-fiber diets or probiotics were associated with poorer response to anti-PD-1 therapy and fewer interferon-gamma-positive cytotoxic T cells in the tumor environment. These experiments provide a plausible mechanism for further research, but animal findings do not establish a human treatment effect. Spencer and colleagues
| Approach studied | What was reported | Evidence boundary |
|---|---|---|
| Reported dietary fiber intake | Higher intake was associated with improved progression-free survival during melanoma checkpoint blockade. | Association in a specific treatment setting; not an established general immune-health intervention. |
| Commercial probiotic supplements | The fiber association was most pronounced among participants who did not report probiotic use. | Association based on reported use; it does not show that all probiotics are harmful. |
| Low-fiber diets and probiotics in mice | Preclinical models showed poorer anti-PD-1 response and changes in tumor immune cells. | Plausible mechanism from animal research, not an established human outcome. |
“Probiotic” is not a single intervention. Products vary by strain, dose, formulation, quality, and intended use. The study’s findings cannot be applied automatically to every probiotic product, health condition, or person. The benefit or risk of a probiotic remains uncertain unless the specific product has been studied for the intended outcome.
People receiving cancer immunotherapy should discuss supplements and substantial dietary changes with their oncology team. The study does not replace individualized cancer or nutrition care.
Disclosure: The melanoma study reported relevant competing interests. Some authors reported patents or patent applications related to microbiome-directed cancer approaches, as well as consulting, honoraria, or industry research-support relationships. Spencer and colleagues
The gut-skin axis remains a research concept
Skin conditions are often included in discussions of the gut and immune system connection. A 2022 review examined potential links among gut microbes, immune signaling, diet, prebiotics, probiotics, antibiotics, and skin conditions including psoriasis, atopic dermatitis, acne vulgaris, rosacea, alopecia areata, and hidradenitis suppurativa. Mahmud and colleagues
The review describes possible pathways through which gut microbes and immune signaling could affect skin health. It also notes that the relevant mechanisms remain unclear. The gut-skin axis is therefore supported by plausible mechanisms and active research, not by an established explanation for every skin disorder. Mahmud and colleagues
The cited review does not establish that a stool test, elimination diet, probiotic, prebiotic, or general gut-health product can treat psoriasis, eczema, acne, rosacea, or other skin conditions. For these interventions, effectiveness is uncertain unless a specific approach has been tested in people with the relevant condition and shown to improve outcomes such as lesions, itch, disease control, or quality of life.
Persistent, painful, widespread, or worsening skin symptoms deserve assessment as skin symptoms rather than being presumed to reflect an intestinal imbalance. Gut-focused products should not replace care for a diagnosed skin condition.
A practical way to assess gut-health claims
Gut-health marketing often begins with a legitimate biological observation and extends it beyond the available evidence. Before acting on a claim, consider the following questions.
- What exactly is being tested or sold? A dietary pattern, fiber supplement, probiotic, antibiotic, stool test, and microbiota-based treatment are different interventions. Evidence for one does not establish benefits for another.
- Who was studied? Findings in people receiving melanoma immunotherapy cannot automatically be applied to healthy adults, children, or people with unrelated conditions.
- What outcome was measured? A shift in gut microbes is not the same as fewer symptoms, fewer infections, better disease control, or improved survival.
- Was the finding an association, an established outcome, or a plausible mechanism? Observational studies can identify associations. Animal work can help test mechanisms. Neither alone establishes that an intervention will improve a human health outcome.
- Is the promise specific? Terms such as “detox,” “repair,” and “boost” do not identify a measurable outcome. A credible claim should explain what changed, for whom, and on what evidence.
Antibiotics can affect gut microbial communities, a point discussed in the 2021 review. Álvarez and colleagues This is an established biological effect, not evidence that avoiding or stopping a prescribed antibiotic will improve health. Antibiotic decisions should be based on the infection or condition being treated and made with a clinician.
Conclusion
The gut is an important site of immune activity, but “70% of immunity lives in your gut” is not a validated statistic. A more accurate description is that intestinal tissues, resident microorganisms, diet-related exposures, and immune signaling interact as part of normal physiology. Álvarez and colleagues
That connection does not make microbiome tests, supplements, or broad dietary rules established immune treatments. In melanoma immunotherapy, reported fiber intake was associated with treatment outcomes in one study, while mouse experiments offered a plausible mechanism requiring further human research. Gut-skin research likewise identifies possible links without establishing gut-focused treatments for common skin conditions. The clearest way to assess a claim is to ask what intervention was studied, in whom, and whether it improved an outcome that matters to patients.
Sources
- Álvarez J, et al. Gut microbes and health. Gastroenterología y Hepatología. 2021.
- Spencer CN, et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021.
- Mahmud MR, et al. Impact of gut microbiome on skin health: gut-skin axis observed through the lenses of therapeutics and skin diseases. Gut Microbes. 2022.
